Vivani Medical, Inc.
NASDAQ:VANIMedical - Devices
+$0.02 today
- Market cap
- $94.71M
- Beta
- 3.29
- P/E (TTM)
- -3.5
- EPS (TTM)
- -$0.33
Volume 0.18M
Average 0.24M
VANI Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Vivani Medical, Inc.NASDAQ: VANI
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin grows, but more slowly than its trailing trend
Q1 FY2026 selling, general & admin of $2.43M rose 3.7% year over year, behind the +9.5% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 11.3% from the prior quarter. Over 3 fiscal years it compounded at +20.6% a year.
Context
- Selling, general & admin increased in 2 of the last 3 fiscal years.
What to watch
Whether selling, general & admin reaches the consensus estimate of $0 (-100.0%) for the fiscal year ending Dec 2026, a slowdown from the +5.6% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $2.43M+11.3% QoQ
- Last fiscal yearDec 2025
- $9.43M+5.6% YoY
- LTMMar 2026
- $9.52M+9.5% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +3.7% | -100.0% | -103.7 pp |
| 1 year | +5.6% | -100.0% | -105.6 pp |
| 3-year CAGR | +20.6% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 9.43M USD
- Year-over-year change
- +5.6%
- 4-year CAGR
- +42.0%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 9.43M | +5.6% |
| FY2024 | 2024-12-31 | 8.93M | -10.7% |
| FY2023 | 2023-12-31 | 10M | +86.1% |
| FY2022 | 2022-12-31 | 5.37M | +131.5% |
| FY2021 | 2021-12-31 | 2.32M | — |
Selling, General & Admin vs competitors
How VANI compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +9.5% is the 4th highest of 8, against a peer median of -2.2%.
- Over three fiscal years its annual growth of +20.6% compares with a peer median of +2.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $78.19M USD | -14.1% | +20.9% | 108.1% | |
| LTM Mar 2026 | $26.33M USD | -2.2% | -17.3% | 171.8% | |
| LTM Mar 2026 | $21.42M USD | +168.1% | — | 20.3% | |
IMAImageneBio Inc | LTM Mar 2026 | $21.2M USD | -9.1% | -2.3% | — |
| LTM Mar 2026 | CA$20.29M CAD | -9.6% | +7.3% | — | |
| LTM Mar 2026 | $9.71M USD | +81.8% | +13.9% | 9251.4% | |
| LTM Mar 2026 | $9.52M USD | +9.5% | +20.6% | — | |
| LTM Mar 2026 | $8.48M USD | +21.4% | -17.7% | — | |
| Peer median (excluding VANI) | — | -2.2% | +2.5% | 139.9% | |
Competitors are the stored peer set for VANI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 357K | 0 | 424K |
| Gross Profit | 0 | 0 | (357K) | 0 | (424K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 11M | 14.17M | 16.97M | 15.75M | 18.13M |
| Selling, General & Admin | 2.32M | 5.37M | 10M | 8.93M | 9.43M |
| Operating Expenses | 13.32M | 21.24M | 26.61M | 24.68M | 27.13M |
| Depreciation & Amortization | 345K | 381K | 357K | 400K | 424K |
| EBITDA | (12.43M) | (19.16M) | (25.3M) | (23.09M) | (26.19M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (13.32M) | (21.24M) | (26.97M) | (24.68M) | (27.56M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 550K | 7.35M | 1.31M | 1.19M | 947K |
| Income Before Tax | (12.77M) | (13.89M) | (25.65M) | (23.49M) | (26.61M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (12.77M) | (13.89M) | (25.65M) | (23.49M) | (26.61M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.33) | (0.17) | (0.50) | (0.43) | (0.43) |
| EPS (Diluted) | (0.33) | (0.17) | (0.50) | (0.43) | (0.43) |
| Weighted Avg Shares | 36.25M | 38.24M | 50.85M | 54.98M | 62.39M |
| Weighted Avg Shares (Diluted) | 36.25M | 38.24M | 50.85M | 54.98M | 62.39M |
Vivani Medical, Inc.
NASDAQ:VANI
Intrinsic Alpha fair value
Locked
Current Price
$1.05
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.